pSivida Corp (PSDV)

3.96
0.02 0.50
NASDAQ : Health Care
Prev Close 3.98
Open 3.96
Day Low/High 3.95 / 3.99
52 Wk Low/High 2.37 / 5.81
Volume 11.51K
Avg Volume 71.70K
Exchange NASDAQ
Shares Outstanding 34.17M
Market Cap 134.30M
EPS 0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle

Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle

Results to Form Part of Planned Applications for Marketing Approvals in EU and US

PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer

PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer

Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience

PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)

PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)

Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit

Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy

Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy

Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society

PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility

PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility

Plan to Facilitate Product Development and Reduce Operating Expenses

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology

PSivida Closes $17.8 Million Offering

PSivida Closes $17.8 Million Offering

Today's Weak On High Volume Stock: PSivida (PSDV)

Today's Weak On High Volume Stock: PSivida (PSDV)

Trade-Ideas LLC identified pSivida (PSDV) as a weak on high relative volume candidate

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: PSivida (PSDV) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified pSivida (PSDV) as a strong on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABBV, ACHN, DBD, DFS, GBLI, IFON, JOBS, LCUT, LOJN, NTL, RAIL, STT, TTWO, UVV Downgrades: AAWW, ASPN, BCH, ECPG, ETE, GSL, LPG, LXU, MW, MYRG, NTK, PCYO, PSDV, SEB, TNGO Initiations: RWLK, TPH, VTAE Read on to get TheStreet Quant Ratings' detailed report: